The insider sales are too small to signal a material change in outlook. Monitor for any upcoming clinical data readouts or regulatory catalysts that could drive the stock, as the company is a clinical-stage biotech. The CEO's sale may be routine portfolio diversification.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 21 $27.52entry
- T+1 · 4mo ago −1.85%α −1.74% · $27.01
- T+5 · 4mo ago −1.13%α +0.10% · $27.21
- T+20 · 3mo ago −3.31%α −5.87% · $26.61
- T+60 · 5w ago −23.69%α −27.66% · $21.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Jon Congleton and CMO David Malcom Rodman sold a combined ~$302K in MLYS stock over a 7-day window, with the CEO's $291K sale representing the bulk. The sales are modest relative to the $2.2B market cap (~0.014%), and the CMO's trades include a same-day derivative exercise and sale, suggesting tax-related or liquidity-driven selling rather than a bearish signal. The cluster is small in dollar terms and lacks the materiality to indicate informed selling.
Key Financial Metrics
Key Facts
- CEO Jon Congleton sold 10,700 shares for ~$291K on 2026-07-13
- CMO David Malcom Rodman sold 416 shares for ~$11K on 2026-07-17, following a derivative exercise
- Total insider sales of ~$302K represent ~0.014% of MLYS's $2.2B market cap
- CMO also exercised 416 derivative shares at $15.44 on 2026-07-17, a non-cash event
- No open-market insider purchases were reported in the cluster window
Financial Impact
Insider sales of ~$302K are immaterial relative to $2.2B market cap
Risk Factors
- Insider selling, while small, could be perceived negatively by retail investors
- Clinical-stage biotech risk: no approved products, reliance on pipeline success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MLYS-1784595659581 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers